Technology & innovation

This archive covers technology and innovation breakthroughs that improve lives, protect the environment, and expand human possibility. From medical devices to clean energy tools, the stories here focus on what’s working and who’s making it happen.

Two people holding hands, for article on Parkinson's infusion device, for article on Onapgo approval

U.S. approves “milestone” Parkinson’s treatment for 2025 release

By / / Good News For Humankind

Onapgo, a new wearable approved by the FDA, will give Americans with Parkinson’s a continuous, non-surgical way to manage their symptoms when it launches in late 2025. The small device delivers a steady infusion of apomorphine under the skin, bypassing the digestive system entirely — a real advantage for a disease that often slows digestion and makes pills unpredictable. In trials, patients cut their daily “off” episodes — those rough stretches when medication wears off and tremors return — by nearly two and a half hours on average. The therapy has quietly helped European patients for about three decades, and its U.S. arrival opens a gentler path for the roughly one million Americans living with Parkinson’s, part of a growing global push toward more humane, individualized care.

A doctor reviewing a prescription pad in a clinical setting for an article about non-opioid pain drug approval

FDA approves first non-opioid pain drug in more than 20 years

By / / Good News For Humankind

The FDA’s approval of Journavx (suzetrigine), a first-in-class non-opioid pain drug, marks the most significant shift in acute pain treatment in over two decades. Developed by Vertex Pharmaceuticals, the drug blocks a specific sodium channel in the peripheral nervous system, stopping pain signals before they reach the brain without engaging the opioid pathways linked to addiction and overdose. Two rigorous clinical trials confirmed its effectiveness for moderate to severe acute pain. With more than 500,000 opioid overdose deaths in the U.S. since 1999, this approval offers patients and doctors a genuinely new choice — one that treats real pain without the shadow of dependence.

Industrial pipes and infrastructure at a coastal energy facility for an article about carbon capture and storage, for article on fusion plasma record, for article on fusion plasma record, for article on fusion endurance record, for article on nuclear fusion ignition

China sets new fusion endurance record of over a thousand seconds

By / / Good News For Humankind

Fusion energy took a real step forward this month: a reactor in China held superheated plasma stable for 1,066 seconds — more than 17 minutes, and over double the 403-second record the same machine set in 2023. The Experimental Advanced Superconducting Tokamak in Hefei pulled it off after engineers doubled the system’s power output while keeping the reaction from collapsing, which is the hardest part of fusion research. Sustained stability like this is exactly what a future fusion plant would need to actually generate continuous electricity. Findings from EAST will also feed directly into ITER, the massive international reactor rising in southern France. It’s a reminder that the dream of clean, nearly limitless energy is being built one patient breakthrough at a time.

A medical researcher reviewing cancer treatment data in a laboratory, for an article about breast cancer immunotherapy

Australian researchers nearly double cure rates for the most common breast cancer

By / / Good News For Humankind

Breast cancer immunotherapy has achieved a breakthrough in Australia, with researchers nearly doubling cure rates for hormone receptor-positive breast cancer — the most common form of the disease, representing roughly 70% of all diagnoses worldwide. A combination of immunotherapy and chemotherapy produced pathological complete responses, meaning no detectable cancer remained at surgery, at rates far exceeding historical norms below 20%. Because HR+ tumors have long resisted immunotherapy, this result marks a significant turning point. With over 2.3 million breast cancer cases diagnosed globally each year, most of them HR+, the potential scale of impact is enormous.

Depiction of intestines, for article on dostarlimab FDA breakthrough designation, for article on dostarlimab FDA Breakthrough Designation

“100% successful” cancer drug gets landmark U.S. FDA approval

By / / Good News For Humankind

A cancer drug called dostarlimab just earned the FDA’s Breakthrough Therapy Designation after eliminating rectal tumors in all 42 patients who completed a Memorial Sloan Kettering trial — with some participants now cancer-free for up to four years. The drug works by helping the immune system recognize and attack tumors carrying a specific genetic signature, sparing patients the surgery, radiation, and chemotherapy that often leave lasting damage to fertility, bowel function, and quality of life. Side effects have been mild, and the new designation could shave years off the path to wider availability. For the roughly 46,220 Americans diagnosed with rectal cancer each year, this hints at a future where beating the disease no longer means trading one kind of suffering for another.

Medical researcher in a lab examining vials related to asthma and COPD treatment and mRNA vaccine development, for article on benralizumab injection, for article on mRNA lung cancer vaccine

Injection beats steroids for asthma and COPD attacks in first major advance in 50 years

By / / Good News For Humankind

Asthma and COPD treatment may be on the verge of its biggest advance in 50 years, after a clinical trial found that a single injection of benralizumab outperformed standard steroid tablets for treating acute attacks. The study, published in Lancet Respiratory Medicine, showed four times fewer treatment failures at three months and 30% fewer follow-up interventions among patients receiving the injection. The trial targeted eosinophilic flare-ups, the biological subtype behind roughly half of all asthma attacks and nearly a third of COPD episodes. Together, the two conditions kill an estimated 3.8 million people annually, yet the standard of care has remained largely unchanged since the 1970s.

Breakthrough genomic test identifies virtually any infection in one go

By / / Good News For Humankind

A single lab test can now identify almost any pathogen — bacteria, virus, fungus, or parasite — from one patient sample, and it correctly pinpointed 86% of neurological infections in a trial of nearly 5,000 patients at UC San Francisco. The method, called metagenomic next-generation sequencing, screens cerebrospinal fluid against a library of more than 68,000 known pathogens and returns answers in about 48 hours, replacing weeks of educated guesswork with a clear picture of what’s actually there. An adapted version for respiratory samples could spot novel viral strains in 12 to 24 hours, offering an early warning system for future outbreaks. If deployed equitably, it could reshape how the world diagnoses infections and detects pandemics before they spread.

Close-up of a human eye with clear cornea, for an article about stem-cell cornea transplant research in Japan, for article on stem-cell cornea transplant

Japanese researchers restore sight with stem-cell cornea transplants in a world first

By / / Good News For Humankind

Stem-cell cornea transplants have been successfully performed on human patients for the first time, with Japanese surgeons using reprogrammed induced pluripotent stem cells to restore vision in three of four participants — results that held for more than a year. Published in The Lancet in 2024, the trial offers a potential path around the global shortage of donor corneal tissue, which currently leaves millions without treatment options. Corneal disease is among the leading causes of blindness worldwide, making a scalable alternative to donor transplants significant. While the trial was small, a 75% sustained success rate in a first-in-human study is a meaningful early result.

Wooden satellite, for article on wooden satellite

World’s first wooden satellite, developed in Japan, heads to space

By / / Good News For Humankind

LignoSat, a 10-centimeter cube of magnolia wood, is now circling Earth as the world’s first wooden satellite — a small experiment with big implications. Built by Kyoto University and Sumitomo Forestry, a company with 350 years of timber expertise, it was delivered to the International Space Station in November 2024. The idea is beautifully simple: when aluminum satellites burn up on reentry, they leave behind metallic particles drifting in the upper atmosphere, but wood combusts cleanly into carbon dioxide and water vapor. Magnolia samples tested in orbit held up without cracking or warping, surprising even the researchers. As tens of thousands more satellites prepare to launch this decade, LignoSat hints that the materials we send skyward matter as much as how we use them.

Blood cells under microscope, for article on smart insulin, for article on lab-grown blood cells

Danish scientists design new form of insulin that automatically switches itself on and off

By / / Good News For Humankind

Smart insulin that reads blood sugar in real time and adjusts its own activity has cleared a major hurdle in animal trials, according to Danish researchers publishing in Nature. The molecule switches on when glucose climbs and powers down as levels normalize, mimicking the feedback loop of a healthy pancreas. That matters because conventional insulin can overshoot and trigger dangerously low blood sugar, a side effect that endangers people living with diabetes every day. Scientists have chased this idea for more than 40 years, and earlier candidates kept stumbling in living bodies. For the more than 500 million people worldwide managing diabetes, an insulin that doses itself would be a quiet revolution — bringing daily care closer to how the body was meant to work.